European Commission logo
English English
CORDIS - EU research results
CORDIS

Microbiome-derived asthma and allergy protective substances for prevention

Project description

Strategies to stop the asthma and allergy epidemic

Asthma affects both children and adults. However, it is the most common chronic disease among children. It is estimated that one in 10 school-age children suffer from asthma. Allergies are also very prevalent, with up to 50 % of children being diagnosed with them. Unfortunately, there is no cure or effective prevention available. The ERC-funded APROSUS project will advance the field of microbiome research towards in-depth characterisation of microbe-derived metabolite complexes to better understand their associated asthma and allergy protective properties. Project work will be based on previous studies carried out by the team, whereby both asthma and allergies were explored together, identifying relevant taxa of the environmental microbiome and discovering microbiome-derived functional agents conferring protection.

Objective

Asthma and allergies are the epidemic of the 21st century after a sharp rise in prevalence since the middle of the last century. Asthma is the most common chronic condition for children – at school age about every 10th pupil is affected in westernized countries. Likewise, allergic illnesses are very prevalent with 30- 50 % of the paediatric population being affected. Currently, there is neither cure nor effective prevention. However, asthma and allergies are illnesses, which are largely environmentally determined. Exposures to the environmental microbiome greatly determine risk and protection from onset of illness in populations of common genetic make-up. My team and I have described relevant taxa of the environmental microbiome in the unique farm studies we pioneered. Very recently, we discovered the microbiome-derived functional agents conferring protection. These epidemiological findings while being scientifically cutting edge, cannot be back translated to children’s and their families’ benefit. My vision is thus to move the field of microbiome research forward towards in depth characterization of microbe-derived metabolite complexes to better understand their associated asthma- and allergy protective properties by advancing both the experimental and the human population-based studies. The interdisciplinary APROSUS Project addresses this research gap. The aims are to characterize and synthetize these functional agents (aim 1), to understand the underlying mechanisms of protection (aim 2) and to validate the findings in the population-based farm studies (aim 3). Thereby we will lay the ground for translation into innovative and effective prevention strategies to stop the asthma and allergy epidemic.

Keywords

Host institution

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Net EU contribution
€ 2 000 000,94
Address
INGOLSTADTER LANDSTRASSE 1
85764 Neuherberg
Germany

See on map

Region
Bayern Oberbayern München, Landkreis
Activity type
Research Organisations
Links
Total cost
€ 2 000 000,94

Beneficiaries (2)